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Abstract Objective: To determine
the therapeutic efficacy and safety of
plasmapheresis in the treatment of
patients with severe sepsis and septic
shock. Design: Prospective, random-
ised, clinical trial with a planned,
midstudy, interim analysis.
Setting: Intensive care unit in a uni-
versity hospital in Archangels, Rus-
sia. Patients: Consecutive patients
with severe sepsis or septic shock.
Interventions: One hundred and six
patients were randomised to receive
either standard therapy or an add-on
treatment with plasmapheresis.
Measurements and results: The pri-
mary endpoint was 28-day survival.
Septic shock was diagnosed in 57%
of the plasmapheresis-treated pa-
tients and 54% of the control pa-
tients. Mean APACHE III score at
entry was 56.4 in the plasmapheresis
group and 53.5 in the control group.
The 28-day, all-cause mortality rate
was 33.3% (18/54) in the plasma-
pheresis group and 53.8% (28/52) in
the control group. This represents a
relative risk for fatal outcome in the
plasmapheresis group of 0.61, an ab-
solute risk reduction of 20.5% and a
number of patients needed to treat of
4.9. Apart from six transient epi-
sodes of hypotension and one aller-
gic reaction to fresh frozen plasma,
no adverse reactions were attribut-
able to the plasmapheresis treatment
in this study. Conclusions: Plasma-
pheresis may be an important adju-
vant to conventional treatment to re-
duce mortality in patients with se-
vere sepsis or septic shock. Plasma-
pheresis is a safe procedure in the
treatment of septic patients. A pro-
spective randomised multicentre trial
is warranted to confirm our results
and to determine which subgroups of
septic patients will benefit most from
this treatment modality.
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Plasmapheresis in severe sepsis 
and septic shock: 
a prospective, randomised, controlled trial
Introduction
Sepsis is an increasingly common cause of morbidity
and mortality, particularly in elderly, immunocompro-
mised and critically ill patients [1]. Estimated mortality
from severe sepsis and septic shock ranges from 20% to
60% [2, 3]. Sepsis therefore represents the leading cause
of death in intensive care units [4, 5], and the incidence
will probably continue to rise because of demographic
trends and increased use of immunosuppressive agents,
broad-spectrum antibiotics and invasive technology. In
recent years many new therapies for sepsis have been
tested in randomised clinical trials. A common concept
of these innovative therapies is the attempt to counteract
the physiological response to sepsis mediators by admin-
istration of specific antibodies, inhibitors and antagonists
directed against these mediators. However, most of these
innovative therapies have failed to have an effect on
mortality [6]. During sepsis, particularly Gram-negative
sepsis, the entire spectrum of host effector molecules are
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released, many of which have been confirmed to be re-
sponsible for the clinical syndrome of sepsis. This sug-
gests that while blocking or down-regulating any single
mediator may modify or at least partially abrogate the
organ dysfunction seen in sepsis, it is highly unlikely
that any single modulatory regimen targetting one single
mediator would be successful in reducing mortality in a
clinical setting of severe sepsis or septic shock. Further-
more, many of the mediators of sepsis are probably yet
undiscovered, and our knowledge of the mediators that
have been discovered is far from complete.
Plasmapheresis is a non-selective method with the po-
tential to remove harmful or toxic mediators from the
circulation. Using fresh-frozen plasma as replacement
fluid, consumed plasma factors are substituted, thereby
possibly restoring the opsonic capacity and improving
the coagulation abnormalities, both of which are dis-
turbed in sepsis. Since 1979 several reports have been
published on plasmapheresis and whole blood exchange
for sepsis [7, 8, 9, 10, 11, 12, 13, 14, 15, 16]. These re-
ports, based on a small number of patients and without
appropriate control patients, are inconclusive and con-
flicting with respect to whether plasmapheresis provides
any beneficial effects in the treatment of sepsis. Conflict-
ing results are also reported in animal studies, which
have sought to evaluate the efficacy of plasmapheresis in
sepsis and septic shock [17, 18, 19].
In Archangels plasmapheresis has been used in the
treatment of sepsis for many years, but the method has
not been evaluated by a proper clinical trial. The aim of
the present study was to determine the therapeutic effica-
cy and safety of plasmapheresis in the treatment of pa-
tients with severe sepsis and septic shock in a prospec-
tive, randomised, controlled trial.
Materials and methods
The protocol was approved by the institutional review board at the
City Emergency Hospital #1. Informed consent was obtained from
all conscious patients enrolled in the study. Delayed consent was
obtained from surviving patients who were unconscious at the
time of enrolment.
Patient selection and definitions
Eligible patients were aged between 17 and 70 years and had se-
vere sepsis or septic shock. Sepsis was diagnosed according to the
criteria proposed by Bone et al. [20]. The systemic inflammatory
response to infection included more than one of the following
clinical manifestations; temperature higher than 38°C or lower
than 36°C, tachycardia (heart rate higher than 90 beats per min),
tachypnoea (respiratory rate more than 20 breaths per min) or hy-
perventilation (PaCO2 less than 4.2 kPa), and leukocytosis (white
blood cell count greater than 12,000/mm3) or leucopenia (white
blood cell count less than 4000/mm3). Severe sepsis was defined
as sepsis associated with organ dysfunction, hypoperfusion abnor-
mality, or sepsis induced hypotension (systolic blood pressure less
than 90 mmHg). Hypoperfusion markers used were lactic acidosis,
oliguria, and alteration in mental status. Septic shock was defined
as sepsis-induced hypotension, persisting despite adequate fluid
resuscitation, along with the presence of hypoperfusion abnormal-
ities or organ dysfunction. Patents with hypoperfusion abnormali-
ties or organ dysfunction receiving inotropic support were consid-
ered to have septic shock even if they had normal blood pressures.
Patients treated for severe sepsis or septic shock in other hospitals
for more than 12 h before they were transferred to City Hospital
#1, and patients with severe underlying disease were not included
in the study. Severe underlying disease includes patients with ter-
minal cancer, terminal cardiac failure, end-stage renal failure and
potentially lethal injuries.
Randomisation, treatment procedures and endpoint
As soon as the diagnosis of severe sepsis or septic shock was es-
tablished, the patients were randomised to receive plasmapheresis
in addition to conventional sepsis treatment or conventional sepsis
treatment alone. The patients were block-randomised in two stages
allowing an interim analysis after inclusion of 50 patients. All pa-
tients received conventional sepsis treatment according to the indi-
cation in each case. This treatment included antibiotics, fluid re-
suscitation (plasma, colloids, and/or crystalloid), surgical proce-
dures, and cardiovascular and ventilatory support when indicated.
Combination therapy of antibiotics was chosen according to
source of infection and micro-organisms suspected to be involved,
and corrected according to positive bacteriological culture and re-
sistance patterns when available. Patients in both groups who did
not have contraindications to anticoagulation therapy received
heparin. Activated partial thromboplastin time, used to monitor
the anticoagulation therapy, was kept below 80 s except during the
periods when patients were undergoing plasmapheresis. Plasma-
pheresis was initiated within 6 h after the diagnosis was estab-
lished. It was repeated once within 24 h in 27 patients in whom
the clinical condition did not improve, or in whom the clinical
condition still deteriorated after the first procedure as judged by
the presence or progression of haemodynamic instability and the
development of organ dysfunction. Plasmapheresis was performed
employing a PF-0.5 (Lvov, Russia), and a DK2-0.3 (Rjazan, Rus-
sia) continuous flow plasmapheresis machines using veno-venous
access. Heparin doses of 200–300 U/kg bodyweight was used as
anticoagulant. Activated clotting time was kept between 250 and
300 s. during plasmapheresis. During each exchange session a vol-
ume of 30–40 ml/kg bodyweight of patient's plasma was ex-
changed with an equal volume of fresh-frozen plasma from heal-
thy donors, diluted with an equal volume of 5% human albumin
solution. The duration of the first plasmapheresis session was
133±23 min and the second session 137±21 min. The mean ex-
change plasma volume during the first session was 1820±402 ml
and 1763±312 ml during the second session.
The patients were followed for 28 days or until they died. For
comparison of disease severity the Acute Physiology and Chronic
Health Evaluation (APACHE) III score was calculated at study en-
try, after 24 h and after 48 h [21]. Primary endpoint was 28-day
survival.
Patient characteristics
The study included 106 consecutive patients (60 men, and 46
women; mean age 44±15 years) treated between December 1994
and March 1997. At study entry 56% of the patients were in septic
shock (31/54 in the plasmapheresis group patients and 28/52 in the
control group). Mean baseline APACHE III score was 54.9±17.4
(56.4 in the plasmapheresis group and 53.5 in the control group).
The largest number of infections originated in the abdomen, with
33 patients in the plasmapheresis group and 16 in the control
group. The next largest group had respiratory tract infections
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(n=12) followed by urinary tract infections (n=10). Except for age
and distribution of sites of infection, there were no statistically
significant differences between the groups with respect to these
baseline characteristics (Table 1). Surgical procedures were per-
formed on 65% (35/54) of plasmapheresis treated patients and on
73% (38/52) of control patients. Inotropes were used in 56%
(30/54) of patients in the plasmapheresis group and in 52%
(27/52) of patients in the control group. Mechanical ventilation
was required by 46% in the plasmapheresis group and by 67% in
the control group (Table 2). 
Statistical analysis
Statistical analysis was performed using SPSS for Windows, ver-
sion 10.0 (SPSS, Chicago, Ill., USA). Univariate comparisons of
baseline characteristics were made by unpaired t test for continu-
ous variables and Fisher's exact test for categorical variables.
Pearson's χ2 was used to test differences in infectious origin be-
tween the two groups. Changes in APACHE III score from base-
line values were assessed by paired t test. Fisher's exact test was
used to test differences in survival between the groups. Multiple
logistic regression was used to assess the effect of the treatment
variable and the baseline demographic and prognostic variables on
survival. The reported mortality rates represent all cause mortality
in the two groups, and the analysis was completed on an intention
to-treat-basis. Data are presented as mean ±SD. Differences were
considered significant at p values less than 0.05. All reported p
values are two-sided.
Results
Efficacy and safety of plasmapheresis
The interim analysis revealed a mortality of 14/25 in the
control group compared to 8/25 in the plasmapheresis
group (n.s.). Consequently the study was continued. No
fatal adverse reactions were attributable to the plasma-
pheresis procedure in this study. Six patients had short
and undramatic periods of hypotension during the plas-
mapheresis procedure, and one patient had an allergic re-
action to fresh-frozen plasma. Two patients in the plas-
mapheresis group died of bleeding. One patient with me-
diastinitis due to a stab wound that penetrated the ab-
dominal aorta, the omentum and the lower part of the oe-
sophagus died of massive rebleeding from the abdominal
aorta 4 days after his last plasmapheresis procedure. The
second patient that died from bleeding had a haemor-
rhagic pancreatitis and died 17 days after the plasma-
pheresis procedure. Thus none of them could be related
to the plasmapheresis procedure. During the first 24 h
APACHE III score decreased by 20% in the plasmapher-
esis group (p<0.001) compared to 8% in the control
group (p<0.05), making the change in APACHE score
from day 1 to day 2 significantly different between the
Table 1 Baseline characteris-
tics in 106 patients with severe
sepsis or septic shock randomly
assigned to plasmapheresis or
not in addition to standard sep-
sis treatment
Variablea Plasmapheresis (n=54) Control (n=52) p
Gender: M/F 34/20 26/26 0.24
Mean age (years) 41±15 48±16 0.03
Septic shock 31 (57%) 28 (54%) 0.84
Mean APACHE III score 56.4±18.8 53.5±15.8 0.40
Mean APACHE III score for respiratory functions
Respiratory rate 5.2±2.6 4.8±2.8 0.42
PaO2 3.5±3.5 2.7±3.1 0.24




Skin/soft tissue 5 5
Female genital 2 7
Brain 3 4
Other sitesb 6 3
a Number of p atients except
where stated otherwise
b Other sites includes three pa-
tients with orthopaedic infec-
tions, one patient with endocar-
ditis, and patients in whom the
site of infection was uncertain,
i.e., five multitrauma patients
and one patient with burn injury
Table 2 Concomitant therapies
during the observation period
in 106 patients with severe sep-
sis or septic shock randomly
assigned to plasmapheresis or
not in addition to standard sep-
sis treatment
Variable Plasmapheresis (n=54) Control (n=52) p
n % n %
Surgery 35 65 38 73 0.41
Inotropes 30 56 27 52 0.85
Anticoagulationa 49 91 48 92 1.0
Mechanical ventilation 25 46 35 67 0.03
Fresh frozen plasma 54 100 43 82 0.001
a Anticoagulation therapy in plasmapheresis group denotes anticoagulation given in addition to the
heparin delivered during the plasmapheresis procedure
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groups (p<0.03). The 28-day all-cause mortality in the
plasmapheresis group was 33.3%, compared to 53.8% in
the control group (p=0.050). This represents a relative
risk of fatal outcome in the plasmapheresis group of 0.61
(95% CI 0.39–0.97), an absolute risk reduction of 20.5%
(95% CI 2%–39%) and a number of patients needed to
treat of 4.9 (95% CI 2.5–50; Fig. 1, Table 3). Correcting
for the variables that were significantly different be-
tween the groups at baseline (age and site of infection)
using multiple logistic regression, reduced the signifi-
cance of the treatment variable on mortality (p=0.07,
odds ratio 0.41, 95% CI 0.15–1.09; Table 4). 
Post-hoc sub-group analysis
A hypothesis generating post-hoc sub-group analysis
was performed in the group of 49 patients with abdomi-
nal infections, which was the only group large enough to
be assessed separately. Mortality in this subgroup was
33% in the plasmapheresis-treated patients and to 69% in
the control group (p<0.05; Table 3). Except for age, no
significant differences were calculated between the two
groups with respect to baseline characteristics (data not
shown).
Discussion
Controlled clinical trials aimed at evaluating the thera-
peutic efficacy and safety of plasmapheresis in the treat-
ment of sepsis have long been needed [22], although
some authors have suggested that such trials would never
be carried out [23]. Our study, the first reported random-
ised study to address this issue, found that patients treat-
ed by plasmapheresis had a significantly higher survival
rate than those receiving conventional treatment alone.
However, patients in the control group were older, and
the study population was heterogeneous with respect to
site of infection, both being factors that could bias the in-
terpretation of the results. Correcting for these factors by
multiple logistic regression diminished the beneficial ef-
fect of plasmapheresis (now with only a trend towards
significance; Table 4).
The APCHE III score dropped in both groups from
day 1 to day 2. However, the change in APACHE III
Fig. 1 Cumulative survival in 106 patients with severe sepsis or
septic shock randomly assigned to plasmapheresis (solid line) or
not (dotted line) in addition to standard sepsis treatment
Table 3 Prognostic score, outcome and cause of death in 106 pa-
tients with severe sepsis or septic shock randomly assigned to
plasmapheresis or not in addition to standard sepsis treatment (n.a.
not assessed, ARDS adult respiratory distress syndrome, DIC dis-
seminated intravascular coagulation)
Variablea Plasmapheresis Control p
(n=54) (n=52)
Mean APACHE III score
Day 1 56.4±18.8 53.5±15.8 0.40
Day 2 44.5±18.5* 49.0±19.7 0.24
Difference days 1–2 11.5±15.6 4.5±15.7 0.03
28-day mortality
Total study population 18 (33.3%) 28 (53.8%) 0.05
Abdominal group 11/33 (33.3%) 11/16 (68.5%) 0.03
Other groups 7/21 (33.3%) 17/36 (47.2%) 0.4
Cause of death
Respiratory failure/ARDS 2 4 n.a.
Cardiovascular 7 10 n.a.
Multiorgan failure 6 13 n.a.
Brain herniation 0 1 n.a.
DIC 1 0 n.a.
Bleeding 2 0 n.a.
a Number of patients except where stated otherwise
* p<0.001 vs. baseline
Table 4 Multiple logistic regression analysis evaluating the ad-
justed effects of unbalanced baseline characteristics and plasma-
pheresis on mortality in patients with severe sepsis or septic shock
Independent variable Odds ratio 95% CI p
Age (10 years)a 1.48 1.03–2.12 0.03
Site of infection 0.04
Abdominal Reference
Female genital 0.54 0.07–4.00
Urological 0.15 0.02–0.93
Lung 4.04 0.74–22.2
Skin/soft tissue 0.41 0.07–2.53
Brain 1.60 0.30–8.62
Other 1.71 0.33–8.88
Plasma exchange 0.41 0.15–1.09 0.07
a Denotes odds ratio by increase of 10 years
score from day 1 to day 2 was significantly better in the
plasmapheresis group. The APACHE score has been
shown to be a reliable predictor of outcome in critically
ill patients in general [24] as well as in patients with sur-
gical and postoperative intra-abdominal infections [25,
26]. Mean APACHE III score in our series was 54.9
(17.4) with a corresponding overall mortality of 43%,
which is somewhat higher than would be expected form
the APACHE score if we compare our material with pre-
vious reports [24]. However, international comparisons
may be biased by differences in laboratory tests, differ-
ences in patient populations and case selections for ICU
treatment. As this may influence the calibration of the
APACHE estimates [27], the most useful and reliable es-
timate to determine the patient's response to therapy is
the relative trend or change in APACHE score from one
day to the next (Table 3). This concept is supported by
Knaus et al. [21], who state that changes in the APACHE
III score on each subsequent day of ICU therapy provide
daily updates in the risk estimates.
Both clinical and experimental studies have shown
that plasmapheresis lowers circulating levels of endo-
toxin and cytokines such as tumor necrosis factor α and
interleukin 1β [10, 18, 28, 29, 30]. Most authors claim
that the beneficial effect of plasmapheresis is due to the
removal of these mediators. However, the beneficial ef-
fect of plasmapheresis is probably not explained solely
by the removal of toxic mediators. Using fresh-frozen
plasma as replacement fluid, the procedure also replen-
ishes deficiencies such as the immunoglobulins IgM and
IgA [11] and coagulation factors and inhibitors such as
proteins C and S and antitrombin III. Plasmapheresis
may thus restore coagulation abnormalities and improve
opsonic capacity and serum bactericidal activity. This
may lead to enhancement of the humoral and cellular in-
flammatory response and normalisation of DIC and clot-
ting parameters [7, 9, 10]. Support for this is given in
placebo-controlled trials which have tested supplemen-
tal immunoglobulin therapy on patients with postopera-
tive sepsis and septic shock [31]. The role of anticoagu-
lation therapy in sepsis is still unsettled, and we cannot
rule out the possibility that the additional heparin deliv-
ered during the plasmapheresis procedure affected out-
come; however, this can be resolved only in future tri-
als.
Using the rather broad sepsis definition proposed by
Bone et al. [20] as inclusion criteria, we obtained a het-
erogeneous study population including patients with both
Gram-negative and Gram-positive sepsis of various ori-
gins. A post hoc analysis in the group of patients with
abdominal sepsis (comprising 46% of the overall study
population) revealed a significantly higher survival rate
in the plasmapheresis group than in the control group,
while the difference in survival for the rest of the study
population was not significant. The bacterial species
with the greatest potential for invasiveness in abdominal
sepsis are considered to be the Gram-negative bacilli 
Escherichia coli and Bacteroides fragilis [32]. The ma-
jority of septic patients successfully treated by plasma-
pheresis have suffered from systemic meningococcal dis-
ease or other Gram-negative sepsis [7, 8, 10, 12, 13, 16].
Most of the experimental studies in favour of plasma-
pheresis have been performed on animals challenged
with Gram-negative bacilli or endotoxin. Our data dem-
onstrating improved survival in patients with abdominal
sepsis following plasmapheresis are in line with these
previous reports and suggest that the beneficial effect of
plasmapheresis in septic patients may be limited to pa-
tients with Gram-negative sepsis.
Due to negative bacteriological cultures or missing
values on more than one-half of the patients, we were
not able to confirm that the antibiotics given had any ef-
fect on the causative micro-organism. Studies have
shown that treatment with appropriate antibiotics may
reduce shock and mortality rate by 50% [33]. It is un-
likely, however, that there is any difference in resistance
pattern between the two groups who both have been
treated with combination therapy of broad-spectrum anti-
biotics in accordance with the local traditions. Further-
more, according to Astiz and Rackow [5], bacteraemia
occurs only in 40–60% of patients with septic shock, and
the causative organism is not isolated in 10–30% of pa-
tients, possibly because of previous exposure to antibiot-
ics. The presented data on mechanical ventilation repre-
sents ventilator treatment after randomisation. As we do
not have the baseline data on mechanical ventilation, we
cannot rule out the possibility that differences in me-
chanical ventilation between the two groups may have
affected outcome. This is unlikely, however, since the
baseline APACHE III score for the respiratory variables
respiratory rate and PaO2 were not significantly different
between the groups.
In conclusion, our study shows that plasmapheresis
can be performed safely in patients with severe sepsis or
septic shock. The data also support the hypothesis that
plasmapheresis reduces mortality in these patients, al-
though unbalanced baseline characteristics prevents us
from making general recommendations based on this
study. A larger scale, phase III, prospective randomised
multicentre trial is needed to confirm our results and to
determine which groups of septic patients will particular-
ly benefit from this treatment modality.
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